Skip to main content

Table 2 Patient characteristics and laboratory parameters at the study inclusion

From: Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients

 

Arm A

(n = 9)

Arm B

(n = 7)

pvalue

Patients’ characteristics

(m + SE)

(m + SE)

 

Age

36.3 ± 6.70

34.7 ± 6.92

0.643

Sex

 

 Male

6 (75.0)

2 (25.0)

0.131

 Female

3 (37.5)

5 (62.5)

 

Weight (kg)

53.2 ± 8.43

49.1 ± 8.93

0.367

Body mass index (BMI)

18.6 ± 3.08

16.5 ± 2.88

0.182

Haemoglobin (g/dL)

8.4 ± 1.95

11.1 ± 3.51

0.062

Leucocytes (103/mL))

5277 ± 5385

5928 ± 3304

0.783

Neutrophils (103/mL))

3795 ± 3663

3638 ± 3134

0.929

Lymphocyte (103/mL))

2417 ± 2224

1442 ± 485

0.277

Monocytes (103/mL))

400 ± 430

271 ± 179

0.472

AST (U/L)

46.5 ± 24.23

48.2 ± 33.10

0.905

ALT (U/L)

41.2 ± 25.43

32.8 ± 22.05

0.500

Creatinine (μmol/L)

98.2 ± 22.04

93.1 ± 21.96

0.652

Total cholesterol (mmol/L) T

143.2 ± 30.30

129.8 ± 25.91

0.368

HDL cholesterol (mmol/L)

44.7 ± 23.63

42.4 ± 16.84

0.827

Amylase (U/L)

131.0 ± 71.31

92.8 ± 53.28

0.266

Total bilirubin (μmol/L)

3.3 ± 2.26

3.8 ± 2.33

0.696

Direct bilirubin (μmol/L)

1.08 ± 0.85

1.45 ± 1.56

0.618

Lymphocytes CD4+ T (cells/μL)

221.1 ± 154.75

285.8 ± 175.39

0.446

Type of tuberculosis

 SPPT

7 (50.0)

7 (50.0)

0.475

 SNPT

2 (100.0)

0 (0.0)

–

WHO HIV stage

 Stage 2

1/9

0/7

0.562

 Stage 3

8/9

7/7

 

Opportunistic infections

 Yes

5/9

3/7

0.500

 No

4/9

4/7

Â